A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection
Rapid Throughput Screening for Human COVID-19 Infection: A ECG Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Karnataka
-
Bengaluru, Karnataka, India
- Sri Jayadeva
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400 012
- King Edward Memorial Hospital
-
-
-
-
-
Madrid, Spain
- Gregorio Maranon Hospital
-
-
-
-
England
-
London, England, United Kingdom
- Imperial College
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- LSUHSC Shreveport
-
-
Michigan
-
West Bloomfield, Michigan, United States, 48322
- Henry Ford Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack Meridian Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult males and females age 18 or greater.
- Undergoing COVID-19 testing by PCR.
- Willing and able to provide informed consent.
- Pregnant females (minimal risk study, no risk from ECG).
Exclusion Criteria:
- Unwilling or unable to provide informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
COVID 19 Detection
Time Frame: One time screening within 4 hours of PCR test
|
Determine the safety and feasibility of the POC AI-ECG's ability to detect active SARS-Cov-2 infection in humans.
|
One time screening within 4 hours of PCR test
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elie F Berbari, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-011415
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed